PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion
Sponsors
Iovance Biotherapeutics Inc., Vaestra Goetalandsregionen, Imcheck Therapeutics
Conditions
MelanomaMetastatic Non-Small-Cell Lung CancerMetastatic or unresectable refractory melanomaPancreatic cancerPreviously treated advanced melanomametastatic
castration-resistant prostate cancer (mCRPC)metastatic
colorectal cancer (CRC)metastatic ovarian cancer
Phase 1
A phase I/II trial of peri- and postoperative treatment with histamine dihydrocloride and low-dose interleukin-2 in patients with primary resectable pancreatic cancer.
Not yet recruitingCTIS2023-506979-10-00
Target: 50Updated: 2024-05-17
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
CompletedCTIS2024-514758-65-00
Start: 2022-05-04End: 2025-10-09Target: 59Updated: 2025-05-20
Phase 2
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
RecruitingCTIS2024-510778-26-00
Start: 2025-12-19Target: 115Updated: 2025-11-26
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
Not yet recruitingCTIS2025-522054-40-00
Target: 69Updated: 2025-12-01